Article
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2026
Cavazzoni A, Pagano Mariano M, Palladini A, Digiacomo G, La Monica S, Bonelli M, Galetti M, Pace I, Roncarati R, Giovannetti E, Aretini P, Minari R, Treccani M, Pluchino M, Lagrasta C A, Angelicola S, Mazzaschi G, Bordi P, Gelsomino F, Agustoni F, Petronini P G, Tiseo M, Ferracin M, Alfieri R
Abstract excerpt
BACKGROUND: Resistance to KRASG12C inhibitors sotorasib and adagrasib, approved for KRASG12C-mutant advanced Non-Small Cell Lung Cancer (NSCLC), involves multiple subclonal events, raising significant concerns about overcoming the resistant phenotype. Cytokines, chemokines, and growth factors are key mediators of drug resistance and targeting their signaling pathways is an emerging strategy in cancer therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.